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Mycobacterial growth inhibition assay
MGIA
Harmonisation
A B S T R A C T
A major challenge to tuberculosis (TB) vaccine development is the lack of a validated immune correlate of
protection. Mycobacterial growth inhibition assays (MGIAs) represent an unbiased measure of the ability to
control mycobacterial growth in vitro. A successful MGIA could be applied to preclinical and clinical post-vac-
cination samples to aid in the selection of novel vaccine candidates at an early stage and provide a relevant
measure of immunogenicity and protection. However, assay harmonisation is critical to ensure that comparable
information can be extracted from different vaccine studies. As part of the FP7 European Research
Infrastructures for Poverty Related Diseases (EURIPRED) consortium, we aimed to optimise the direct MGIA,
assess repeatability and reproducibility, and harmonise the assay across different laboratories. We observed an
improvement in repeatability with increased cell number and increased mycobacterial input. Furthermore, we
determined that co-culturing in static 48-well plates compared with rotating 2ml tubes resulted in a 23% in-
crease in cell viability and a 500-fold increase in interferon-gamma (IFN-γ) production on average, as well as
improved reproducibility between replicates, assay runs and sites. Applying the optimised conditions, we report
repeatability to be<5% coefficient of variation (CV), intermediate precision to be<20% CV, and inter-site
reproducibility to be<30% CV; levels within acceptable limits for a functional cell-based assay. Using relevant
clinical samples, we demonstrated comparable results across two shared sample sets at three sites. Based on
these findings, we have established a standardised operating procedure (SOP) for the use of the direct PBMC
MGIA in TB vaccine development.
1. Introduction
Tuberculosis (TB) is a major global health problem, with 10million
new cases and 1.6million deaths in 2017 (WHO, 2018). BCG, the only
currently available TB vaccine, has poor efficacy against adult pul-
monary disease in the tropics, where TB incidence is greatest (Colditz
et al., 1994). Given the high rates of infection, insufficiency of BCG and
the rising threat from drug-resistant TB (WHO, 2018), an effective
vaccine is urgently required. However, vaccine development is ham-
pered by the lack of a validated immune correlate of protection from TB
(Ottenhoff et al., 2012). Such a correlate or biomarker would aid in the
selection of novel vaccine candidates at an early stage and provide a
relevant measure of immunogenicity in phase I trials. In the absence of
such a biomarker, the protective potential of a vaccine can only be
determined by comparing it to BCG in costly large-scale, long-term
phase III field efficacy trials (Ottenhoff et al., 2012).
Mycobacterial growth inhibition assays (MGIAs) represent an al-
ternative to single biomarkers based on predefined individual immune
parameters; instead offering an unbiased measure of the functional
ability of post-vaccination whole blood or cell samples to control
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mycobacterial growth in vitro (Tanner et al., 2016). A successful MGIA
ie. one that is validated against clinical outcomes such as protection
against natural or experimental mycobacterial infection or disease,
would greatly facilitate TB vaccine development, decreasing the time
and resources required for preclinical evaluation. It may also aid in the
selection of candidates going forward to preclinical virulent M.tb
challenge experiments, in line with the principles of the 3Rs (Replacing,
Reducing and Refining the use of animals in scientific research) (Tanner
and McShane, 2016). Once biologically validated in preclinical models,
bridging to the use of human samples would allow evaluation of pro-
tective potential in the target species. Furthermore, MGIAs offer a
tractable model for the investigation of immune mechanisms under-
lying mycobacterial control (de Vallière et al., 2005; Smith et al., 2016;
Chen et al., 2016; Tanner et al., 2016, 2017; Joosten et al., 2018).
Several MGIAs have been reported in the literature (Worku and
Hoft, 2000; Cheon et al., 2002; Kampmann et al., 2004; Parra et al.,
2009; Fletcher et al., 2013; Tanner et al., 2016; Joosten et al., 2018)
and optimisation and harmonisation efforts have been made, including
the formation of working groups and publication of protocols (Zelmer
et al., 2015; Brennan et al., 2017; Kaufmann et al., 2017). However,
such assays are technically demanding and to date none has been sys-
tematically assessed for reproducibility or standardised and validated
across laboratories for use in TB vaccine development. Assay harmo-
nisation is critical to ensure that comparable information can be ex-
tracted from ongoing and future preclinical and clinical vaccine trials
conducted across different organisations and settings, and with dif-
ferent vaccine candidates. Tuomela et al. (2005) describe precision as a
fundamental assay validation parameter, encompassing three levels:
repeatability, intermediate precision and reproducibility (Tuomela
et al., 2005). Repeatability (intra-assay precision) measures the varia-
tion between multiple determinations of a single sample in a single test
run, while intermediate (inter-assay) precision considers the variation
between multiple measures of a single sample analysed in different
assay runs. Reproducibility is concerned with the variation between
multiple determinations of a single sample analysed at different la-
boratories or sites (Tuomela et al., 2005).
European Research Infrastructures for Poverty Related Diseases
(EURIPRED) was a European Commission-funded Framework Program
7 consortium project that ran from 2013 to 2017. The overall goal was
to coordinate and integrate international resources into a single spe-
cialised infrastructure to support European TB, HIV, Malaria and
Hepatitis B/C studies from early drug, vaccine and microbicide dis-
covery to clinical trials. EURIPRED was comprised of several work
packages including resource management and quality assurance,
sample selection and characterisation of biological materials, develop-
ment and evaluation of reference reagents, and dissemination and
training. Work package 5, standardisation and harmonisation of assays,
aimed to select key immunological assays currently used in vaccine
development, conduct harmonisation experiments and define standar-
dised SOPs for dissemination.
We focussed on the optimisation and harmonisation of the direct
MGIA, based on the methods of Wallis et al. (2001) (Wallis et al., 2001)
and recently adapted for use in TB vaccine studies (Fletcher et al., 2013;
Brennan et al., 2017). This MGIA was selected due to its relative sim-
plicity, the use of standardised reagents and equipment, and advantages
of the BACTEC MGIT quantification system over traditional colony
counting (Brennan et al., 2017). Peripheral blood mononuclear cells
(PBMC) were chosen as the use of cryopreserved cells aids in transfer-
ability to different trial sites, eliminating the need to evaluate samples
in real time using fresh material and enabling direct comparison of pre-
and post-vaccination samples in a single experiment. Optimisation of
various assay parameters was conducted, including multiplicity of in-
fection (MOI), lysis reagents and co-culture methodology. Outcomes for
shared sample sets were compared across three different laboratories
and repeatability, intermediate precision and reproducibility were as-
sessed under different assay conditions. Based on these findings, a




Samples used in the optimisation experiments were obtained from
local blood transfusion services as buffy coats. PBMC were processed
and cryopreserved at one site and vials distributed to the other three
laboratories.
The phase of the project in which the assay was applied to clinically
relevant samples used either PBMC from healthy Dutch donors enrolled
in a BCG vaccination study that was approved with protocol P12.087
(Boer et al., 2015), or PBMC from healthy UK adults aged 18–55 from a
BCG vaccination study that was approved by the Oxfordshire Research
Ethics Committee (C00.219) (McShane et al., 2004). Samples were also
obtained from healthy adult volunteers at the London School of Hy-
giene and Tropical Medicine who were either BCG naïve or historically
vaccinated, and who gave informed, written consent. The Ethics Com-
mittee of the London School of Hygiene and Tropical Medicine (ref.
5520) gave approval for the use of these samples. Samples for the final
harmonisation experiment were taken from a study of BCG vaccination
in healthy UK adults (NCT02380508) conducted at the Jenner Institute,
University of Oxford, which was approved by NRES Committee South
Central - Oxford B (REC ref. 15/SC/0022). Volunteers were aged be-
tween 18 and 45 years with no evidence of latent M.tb infection. In-
dividuals received a single intradermal dose of 2-8×105 CFU of BCG
SSI and bloods were taken pre-vaccination at day 0, and days 2, 4, 7,
10, 14, 21, 28 and 84 post-vaccination.
All methods used in the clinical trials described were carried out in
accordance with the ethical principles set forth in the Declaration of
Helsinki as agreed by the World Medical Association General Assembly
(Washington 2002), ICH Good Clinical Practice (GCP) and local reg-
ulatory requirements. All volunteers gave informed consent after the
nature and possible consequences of the studies had been fully ex-
plained.
2.2. Sample processing
PBMC were isolated from buffy coat or heparinised peripheral blood
samples using density centrifugation. Cells were counted, resuspended
in foetal bovine serum (FBS) and incubated at 4 °C for 30min. An equal
volume of FBS containing 20% dimethylsufoxide was then added and
cells aliquoted at a concentration of 5–10×106 cells per cryovial,
frozen overnight at −80 °C and transferred to liquid nitrogen storage
the following day. Cryopreserved PBMC were thawed in a water bath at
37 °C until a small amount of frozen material remained. Samples were
gradually added to 10ml RPMI (containing 10% FBS and 2mM L-glu-
tamine) using a Pasteur pipette. The cryovial was rinsed using 1ml of
fresh medium and added to the corresponding tube, which was then
centrifuged at 1500 rpm for 5min. Supernatants were poured off and
cells resuspended at an approximate concentration of 2–3×106 cells
per ml of RPMI (containing 10% foetal calf serum and 2mM L-gluta-
mine), and 2 μl/ml of 25 U benzonase (final concentration 50 U/ml)
added to each tube. Cells were rested at 37 °C for 2 h with 5% CO2
before counting.
2.3. Direct PBMC MGIA
2.3.1. Mycobacterial stock preparation
In-house BCG Pasteur stocks were grown in Middlebrook 7H9
medium with 10% OADC to mid-log phase then divided into 1ml ali-
quots and stored at −80 °C until required. Aliquots were thawed at
room temperature immediately prior to inoculation and diluted to the
correct concentration (to give a final assay concentration of 500 CFU
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per culture) in RPMI (containing 2mM L-glutamine and 25mM HEPES).
For harmonisation experiments, frozen aliquots of a single batch of BCG
Pasteur stock (provided by Aeras, Rockville, USA) grown in
Middlebrook 7H9 medium with 10% OADC and 0.05% tyloxapol were
circulated and serially diluted prior to inoculation in a standardised
way between sites.
2.3.2. In-tube protocol
The in-tube direct PBMC MGIA was performed as previously de-
scribed (Fletcher et al., 2013). Briefly, 2ml screw-cap tubes containing
1× 106 PBMC and ~500 CFU BCG Pasteur (unless otherwise specified)
in a total volume of 600 μl RPMI (containing 10% pooled human serum,
2mM L-glutamine and 25mM HEPES) were incubated on a 360° rotator
(VWR International) at 37 °C for 96 h. Where specified, cells were lysed
at the end of the culture period by centrifuging tubes at 12000 rpm for
10min, removing supernatant and adding 500 μl sterile water (or other
lysis agent as specified) to the pellet before pulse vortexing and trans-
ferring to BACTEC MGIT tubes supplemented with PANTA antibiotics
(polymyxin B, amphotericin B, nalidixic acid, trimethoprim and azlo-
cillin) and OADC enrichment broth (Becton Dickinson, UK). For ex-
periments where cells were not lysed, cultures at the end of the 96 h
period were transferred directly to supplemented BACTEC MGIT tubes.
2.3.3. 48-well plate protocol
48 well plates containing 3× 106 PBMC and ~500 CFU BCG
Pasteur in a total volume of 600 μl RPMI (containing 10% pooled
human serum or autologous serum where available and specified, 2mM
L-glutamine and 25mM HEPES) per well were incubated at 37 °C for
96 h. At the end of the culture period, cultures were added to 2ml
screw-cap tubes and centrifuged at 12000 rpm for 10min. During this
time, 500 μl sterile water was added to each well to lyse adherent
monocytes. Supernatants were removed from the 2ml screw-cap tubes,
and water from the corresponding well added to the pellet. Tubes were
pulse vortexed and the lysate transferred to BACTEC MGIT tubes sup-
plemented with PANTA antibiotics and OADC enrichment broth
(Becton Dickinson, UK).
2.3.4. Mycobacterial quantification
At the end of both protocols, tubes were placed on the BACTEC 960
machine (Becton Dickinson, UK) and incubated at 37 °C until the de-
tection of positivity by fluorescence. On day 0, duplicate direct-to-MGIT
viability control tubes were set up by inoculating supplemented
BACTEC MGIT tubes with the same volume of mycobacteria as the
samples. The time to positivity (TTP) read-out was converted to log10
CFU using stock standard curves of TTP against inoculum volume and
CFU. Results are presented as growth ratio which is calculated as log10
CFU of sample/log10 CFU of control.
2.3.5. Assay harmonisation
Steps were taken to ensure consistency across sites as far as possible
for the harmonisation experiments, including use of the same batch of
BCG Pasteur stock preparation diluted in the same series of dilutions at
each site, circulating aliquots of the same cryopreserved PBMC isolated
at one site, and exchange of protocols with specific details for each
experiment. Operator training was conducted between sites at the start
of the project in the standard in-tube protocol.
2.4. Cell viability studies
Cell viability at the end of the 96 h culture period was quantified by
trypan blue exclusion. A 0.4% solution of trypan blue (Sigma Aldrich,
MO, USA) was prepared in buffered isotonic salt solution (pH 7.2–7.3)
and 0.1ml of trypan blue stock solution added to 0.1ml PBMC. A
haemocytometer slide was loaded and examined under a microscope.
The percentage of viable cells was calculated as [1-(number of blue
staining cells ÷ number of total cells)] x 100, and corrected for the
dilution factor.
2.5. IFN-γ ELISA
IFN-γ concentration in MGIA culture supernatants at the end of the
96 h period was determined using the Quantikine® ELISA kit (R&D
Systems, Inc. MN, USA) according to the manufacturer's instructions.
Briefly, samples were diluted 1:1 with assay diluent and incubated for
2 h at room temperature before aspirating each well and washing 4
times using wash buffer. 200 μl of human IFN-γ conjugate was added to
each well and incubated for 2 h at room temperature followed by 4
washes with wash buffer. Substrate solution (200 μl) was added to each
well and incubated for 30min in the dark at room temperature, fol-
lowed by 50 μl of stop solution. The optical density (OD) of each well
was determined using a microplate reader set to 450 nm. Duplicate
readings were averaged and the average zero optical density subtracted.
A standard curve was generated to convert OD values to concentration
in pg/ml.
2.6. Statistics
Data was analysed using GraphPad Prism v.7 and IBM SPSS v.25.
Normality of data was determined using a Shapiro-Wilk test. For
parametric data with multiple groups, a one-way ANOVA or repeated-
measured ANOVA was conducted followed by a Dunn's post-test. For
comparisons between two groups of normally-distributed data, a t-test
or paired t-test was used. For non-parametric data with multiple groups,
a Kruskal-Wallis or Friedman test was conducted followed by a Dunn's
post-test. For comparisons between two groups of non-parametric data
or small sample size, a Mann Whitney or Wilcoxon matched-pairs
signed rank test was conducted. A Spearman's rank correlation was used
to determine associations between two different measures. For de-
termination of intra-assay precision, intermediate (inter-assay) preci-
sion and inter-site reproducibility, the coefficients of variation (stan-
dard deviation/mean x 100) and intra-class correlation coefficients
(two-way mixed model, consistency agreement, single measures) were
calculated using raw TTP values.
3. Results
3.1. Repeatability is improved with increased cell number and increased
numbers of mycobacteria
Human PBMC from 4 donors at a concentration of either 1, 3 or
5×106 cells per culture were inoculated with either 50 or 500 CFU of
BCG Pasteur in the in-tube direct PBMC MGIA conducted at three dif-
ferent laboratory sites. On average, intra-assay repeatability between
replicate cultures was improved with increased cell input and with
increased mycobacterial inoculum. The mean CVs for the replicate
cultures under the different assay conditions are shown in Table 1.
3.2. Lysis method does not affect numbers of BCG recovered
Quantification of BCG at the end of the 96 h co-culture period is a
critical step in assessing mycobacterial growth inhibition. Intracellular
BCG is released by lysis of host cells before addition of the cultures to
BACTEC MGIT tubes using sterile water (Fletcher et al., 2013). We
compared mycobacterial recovery under 5 different cell lysis condi-
tions: (1) None, (2) Sterile water, (3) Phosphate Buffered Saline (PBS)
with Tween 20, (4) 0.2% Saponin and (5) 0.067% Sodium Dodecyl
(lauryl) Sulfate (SDS) across three different laboratory sites. While an
in-house BCG Pasteur stock was used at site 1, sites 2 and 3 used two
different batches of the same stock provided by Aeras. BCG recovery
was comparable across conditions, including no lysis, at all sites
(Fig. 1a–c).
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3.3. Application of preliminary protocol to relevant clinical samples
The preliminary MGIA protocol (1×106 PBMC and 500 CFU of
BCG in 2ml screw-cap tubes with no lysis at the end of the culture
period) was applied to relevant clinical samples at each of the three
sites. At site 1, samples were available from 3 volunteers at baseline and
weeks 4, 8, 12 and 52 post-BCG vaccination. There was a trend towards
improved control of mycobacterial growth following BCG vaccination
up to week 12, but this was not statistically significant (Fig. 2a). At site
2, samples were available from 6 BCG-naïve and 6 historically BCG
vaccinated volunteers. Historically vaccinated volunteers demonstrated
significantly improved control of mycobacterial growth compared with
naïve volunteers (p= .001, Mann-Whitney U test, Fig. 2b). At site 3,
samples were available from 8 volunteers at baseline and weeks 2 and 4
post-BCG vaccination. There was a slight trend towards improved
control of mycobacterial growth following BCG vaccination, but this
was not statistically significant (Fig. 2c). These findings led to efforts to
further optimise the protocol by investigating the use of static 48-well
plates in place of rotating screw-cap tubes.
3.4. Cell viability and IFN-γ production is improved by co-culturing in static
48-well plates compared with rotating screw-cap tubes
3×106 human PBMC from 12 donors (one of which was excluded
due to poor cell recovery post-thawing) were co-cultured with
~500 CFU of BCG Pasteur in either sealed rotating screw-cap tubes or
in static 48-well plates with CO2. At the end of the 96 h culture period,
cell viability was assessed by trypan blue exclusion, and IFN-γ pro-
duction was measured by ELISA. Cell viability was significantly greater
in 48-well plates compared with rotating screw-cap tubes (p < .0001,
paired t-test, Fig. 3a). There was a significant correlation between cell
viability in screw-cap tubes and 48-well plates (r=0.85, p= .0007,
Spearman's correlation), but no correlation between cell viability and
mycobacterial growth in the MGIA (r=−0.04, p= .92, Spearman's
correlation). IFN-γ concentrations were significantly higher in the su-
pernatants of co-cultures in 48-well plates compared with those in
screw-cap tubes (p= .003, Wilcoxon matched-pairs signed rank test,
Fig. 3b), and there was a significant correlation between IFN-γ con-
centration and cell viability (r=0.47, p= .03, Spearman's correlation).
There was also a significant correlation between IFN-γ concentration in
the MGIA supernatant and volunteer PPD status as measured by PPD
stimulation index (r=0.86, p= .0006, Spearman's correlation,
Fig. 3c), but no association between IFN-γ concentration and myco-
bacterial growth in the MGIA (r=−0.12, p= .73, Spearman's corre-
lation, Fig. 3d).
3.5. Repeatability, intermediate precision and inter-site reproducibility is
improved by co-culturing in static 48-well plates compared with rotating
screw-cap tubes
Human PBMC from 12 donors were assessed by MGIA with co-
cultures in either sealed rotating screw-cap tubes or in static 48-well
plates with CO2. Each sample was assayed in triplicate to assess intra-
assay repeatability and the experiment repeated twice on different days
to assess intermediate (inter-assay) precision. This process was repeated
twice across three different sites to evaluate inter-site reproducibility.
In run 1, intra-assay repeatability between replicate cultures, as
measured by CV, was significantly improved when using 48-well plates
compared with rotating screw-cap tubes at site 1 (p= .001, Wilcoxon
matched-pairs signed rank test, Fig. 4a). At site 2, a significant outlier
was identified using the maximised normalised residual (Grubb's) test.
Following exclusion of this outlier, repeatability was significantly
greater using 48-well plates compared with rotating screw-cap tubes at
this site (p= .04, Wilcoxon matched-pairs signed rank test). In run 2,
intra-assay repeatability was significantly improved when using 48-well
plates compared with rotating screw-cap tubes at sites 1 and 2
(p= .001 and p= .003 respectively, Wilcoxon matched-pairs signed
rank test, Fig. 4b). There was a trend towards improved repeatability at
site 3 across both runs but this was not statistically significant. The
mean intra-class correlation coefficients (ICCs) and CVs for the replicate
cultures under the different assay conditions are shown in Table 2.
Intermediate (inter-assay) precision between experiments was de-
termined by conducting the direct PBMC MGIA using the same sample
set at the same site on two different days (henceforth referred to as
‘runs’). Intermediate precision, as measured by CV, was significantly
Table 1
Repeatability is improved with increased cell number and increased myco-
bacterial input. Human PBMC from 4 donors at a concentration of either 1, 3 or
5×106 cells per culture were inoculated with either 50 or 500 CFU of BCG
Pasteur in the in-tube direct PBMC MGIA conducted at three different labora-
tory sites. Median coefficient of variation (CV) values are shown at each site and
averaged across sites to give the mean CV value for each MOI condition.
CFU Cell No. (×106) CV (%)
Site 1 Site 2 Site 3 Mean
500 1 2.09 4.59 5.69 4.12
3 2.09 1.04 8.93 4.02
5 5.00 0.55 2.23 2.59
50 1 4.65 5.89 11.75 7.43
3 3.42 4.62 11.79 6.61
5 1.51 3.52 13.44 6.16
Fig. 1. Lysis method does not affect amount of BCG recovered. Mycobacterial recovery following the direct PBMC MGIA in 2ml screw-cap tubes was assessed using
five different cell lysis conditions: none, sterile water, Phosphate Buffered Saline (PBS) with Tween 20 (PBS-T), 0.2% Saponin (Sap), and 0.067% Sodium Dodecyl
(lauryl) Sulfate (SDS) at three different laboratory sites using different donor PBMC (n=2 or n=3 donors per condition) at each site (site 1= a, site 2=b, site
3= c). Data are expressed as median values with interquartile range. TTP= time to positivity by BACTEC MGIT.
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improved when using 48-well plates compared with rotating screw-cap
tubes at site 2 (p= .002, Wilcoxon matched-pairs signed rank test,
Fig. 4c). There was a trend towards improved intermediate precision
with 48-well plates at sites 1 and 3 but this was not statistically sig-
nificant. The mean ICCs and CVs for the two runs under the different
assay conditions are shown in Table 3. Inter-site reproducibility was
determined by conducting the direct PBMC MGIA using the same
sample set at three different laboratories repeated in two separate runs.
Inter-site reproducibility, as measured by CV, was significantly im-
proved when using 48-well plates compared with rotating screw-cap
tubes in both runs 1 and 2 of the experiment (p= .0005 and p= .02
respectively, Wilcoxon matched-pairs signed rank test, Fig. 4d). The
mean ICCs and CVs across the three sites under the different assay
conditions are shown in Table 4.
There was no association between mycobacterial growth measured
using the in-tube protocol and the 48-well plate protocol across any of
the three sites, as indicated by negative ICC values (data not shown).
However, this sample set was homogeneous with similar levels of
growth control across volunteers (range= 0.29 and 0.13 log10 CFU for
the in-tube and 48-well plate protocols respectively), resulting in a low
signal-to-noise ratio. When tested in an additional sample set with a
broader dynamic range (range=0.66 and 0.59 log10 CFU respectively),
a similar pattern of control across the individuals was observed in a
direct comparison of the two protocols described here with an ICC of
0.54 (moderate agreement) (Supplementary Fig. 1a–b).
3.6. Assay harmonisation using relevant clinical samples
Cryopreserved cells were taken from adult volunteers who were
either BCG naïve or historically BCG vaccinated and the direct PBMC
Fig. 2. Application of preliminary SOP to relevant clinical samples. The preliminary MGIA protocol (1× 106 PBMC, 500 CFU BCG in 2ml screw-cap tubes with no
lysis) was applied to relevant clinical samples at each of the three sites. At site 1, samples were available from 3 volunteers at baseline and weeks 4, 8, 12 and 52 post-
BCG vaccination (a). At site 2, samples were available from 6 BCG-naïve and 6 historically BCG-vaccinated volunteers (b). At site 3, samples were available from 8
volunteers at baseline and weeks 2 and 4 post-BCG vaccination (c). Growth ratio= log10(CFU of sample/CFU of control). Each point represents the mean of 2
technical co-culture replicates of the same sample where filled circles are BCG unvaccinated and open circles are BCG vaccinated, and lines represent the group
median values with interquartile range. For (a and c), a Friedman test was performed followed by Dunn's post-test for multiple comparisons; there were no
statistically significant differences between time-points. For (b), a Mann-Whitney U test was performed, where ** indicates a p-value of< .01.
Fig. 3. Cell viability and IFN-γ production is im-
proved by co-culturing in static 48-well plates com-
pared with rotating screw-cap tubes. 3× 106 human
PBMC from 12 donors (one of which was excluded
due to poor cell recovery post-thawing) were co-
cultured with BCG Pasteur in either sealed rotating
screw-cap tubes (T, filled circles) or static 48-well
plates with CO2 (P, open circles). At the end of the
96 h culture period, cell viability was assessed by
trypan blue exclusion (a), and IFN-γ concentration in
the culture supernatants was measured by ELISA (b).
The association between IFN-γ concentration in the
MGIA culture supernatants and volunteer PPD status,
as measured by PPD stimulation index (ratio of IFN-γ
concentration produced by cells cultured for 72 h in
the presence of PPD and those cultured without an-
tigen), was determined for the same 12 donors (c).
Mycobacterial growth in the MGIA was also mea-
sured using the 48-well plate protocol and the asso-
ciation with IFN-γ concentration in the 96 h super-
natants was determined (d). TTP= time to positivity
by BACTEC MGIT. Each point represents the mean of
2 or 3 technical co-culture replicates of the same
sample and lines represent the group mean values
with SEM. For (a) and (b), a Wilcoxon matched-pairs
signed rank test was performed, where ** indicates a
p-value of< .01, and **** indicates a p-value
of< .0001. For (c) and (d), a Spearman's correlation
was performed.
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MGIA performed in duplicate across three different sites. There was no
overall difference in MGIA outcome between naïve and historically
vaccinated volunteers observed at any of the three sites using either the
in-tube (Fig. 5a) or 48-well plate (Fig. 5b) protocols. The intra-assay
repeatability, as measured by CV, was significantly improved when
using 48-well plates compared with rotating screw-cap tubes at sites 1,
2 and 3 (p= .02, p= .03 and p= .01 respectively, Wilcoxon matched-
pairs signed rank test, Fig. 5c). Inter-site reproducibility was not dif-
ferent between assay conditions (Fig. 5d).
In a second round of experiments, cryopreserved cells were taken
from UK adult volunteers at baseline and 12weeks post-BCG vaccina-
tion and the direct PBMC MGIA performed across three different sites
using the optimised 48-well plate protocol only. In order to validate
detection of a ‘positive response’, volunteer samples were selected
based on a) demonstrating improved control of mycobacterial growth
following BCG vaccination as measured at the trial site and b) having
sufficient availability of cryopreserved PBMC to conduct a comparison
across three different sites. 9 volunteers fulfilled these criteria and this
sample set was circulated for MGIA analysis. A significant improvement
in mycobacterial growth inhibition following BCG vaccination was
observed at all three sites (p= .0007, p= .01 and p= .0002 for sites 1,
2 and 3 respectively, paired t-test, Fig. 6a–c). Sample replicates were
not assayed in this single-run experiment due to cell availability, and
therefore it was not possible to calculate intra-assay repeatability or
intermediate precision. However, inter-site reproducibility was<20%
CV for both baseline and day 84 samples (data not shown).
3.7. EURIPRED direct PBMC MGIA SOP
The detailed optimised Standard Operating Procedure (SOP) for the





While several MGIAs have been described in the literature for use in
mice, cattle and humans (reviewed in Tanner et al., 2016), none has
been systematically assessed for reproducibility or standardised across
laboratories. The aims of the study described were to optimise, stan-
dardise and harmonise the direct PBMC MGIA to ensure that compar-
able results are generated by TB vaccine studies conducted at different
organisations and settings.
Fig. 4. Repeatability, intermediate precision and
inter-site reproducibility is improved by co-cul-
turing in static 48-well plates compared with ro-
tating screw-cap tubes. Human PBMC from 12 do-
nors were co-cultured with BCG Pasteur in either
sealed rotating screw-cap tubes using 1× 106
PBMC per culture (T, filled circles) or static 48-well
plates with CO2 using 3× 106 PBMC per culture (P,
open circles). At the end of the 96 h culture period,
the TTP was determined using the BACTEC MGIT
system. Each sample was assayed in triplicate to
assess intra-assay repeatability in two different
assay runs (a) and (b) and the experiment repeated
twice on different days to assess intermediate (inter-
assay) precision (c). The same sample set was tested
at three different laboratory sites in two separate
runs to evaluate inter-site reproducibility (d). Each
point represents the mean of 2 or 3 technical co-
culture replicates of the same sample and lines re-
present the group median values with interquartile
range. A Wilcoxon matched-pairs signed rank test
was performed between groups, where * indicates a
p-value of< .05, ** indicates a p-value of< .01,
and *** indicates a p-value of< .001.
CV= coefficient of variation.
Table 2
Repeatability is improved by co-culturing in static 48-well plates compared
with rotating screw-cap tubes. Human PBMC from 12 donors were co-cultured
with BCG Pasteur in either sealed rotating screw-cap tubes or in static 48-well
plates with CO2. At the end of the 96 h culture period, the amount of BCG
remaining was quantified using the BACTEC MGIT system. Each sample was
assayed in triplicate to assess intra-assay repeatability and the experiment re-
peated twice on different days across three different sites. Intraclass correlation
coefficient (ICC) and median coefficient of variation (CV) values are shown at
each site and averaged across sites for each condition.
ICC CV (%)
Site 1 Site 2 Site 3 Mean Site 1 Site 2 Site 3 Mean
Screw-cap tubes 0.35 0.58 0.33 0.42 4.44 3.22 4.38 4.01
48-well plates 0.81 0.40 0.66 0.62 1.17 1.51 1.74 1.47
Table 3
Inter-assay precision is improved by co-culturing in static 48-well plates com-
pared with rotating screw-cap tubes. Human PBMC from 12 donors were co-
cultured with BCG Pasteur in either sealed rotating screw-cap tubes or in static
48-well plates with CO2. At the end of the 96 h culture period, the amount of
BCG remaining was quantified using the BACTEC MGIT system. The experiment
was repeated twice on different days across three different sites. Intraclass
correlation coefficient (ICC) and median coefficient of variation (CV) values are
shown at each site and averaged across sites for each condition.
ICC CV (%)
Site 1 Site 2 Site 3 Mean Site 1 Site 2 Site 3 Mean
Screw-cap tubes 0.46 0.48 0.11 0.35 16.62 12.18 2.09 10.30
48-well plates 0.47 0.71 0.44 0.54 13.17 4.68 1.49 6.45
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The finding that intra-assay repeatability is improved by increasing
cell concentration or mycobacterial input is consistent with previous
work by Zelmer et al. (2016) using the direct mouse splenocyte MGIA
(Zelmer et al., 2016). This study determined that the effect size between
naïve and BCG vaccinated mice was also greatest using the highest cell
and mycobacterial inputs (Zelmer et al., 2016). Ideally the magnitude
of growth inhibition in clinical samples following vaccination would be
compared under different multiplicity of infection (MOI) conditions as
in the mouse study but this was not possible due to limited cell avail-
ability. Based on a rationalised compromise between our reproduci-
bility findings and the limitations of clinical sample collection, we se-
lected 3×106 PBMC and 500 CFU of BCG Pasteur as the human assay
conditions for further evaluation. Applying different lysis agents (or
indeed removing the lysis step) did not impact BCG recovery, likely due
to the fact that end-of-culture samples are added to BACTEC MGIT
tubes containing Middlebrook 7H9 broth in which cells would naturally
lyse, releasing intracellular mycobacteria for quantification. This out-
come was consistent across the three sites despite the use of different
BCG Pasteur stocks between sites 1 and 2/3, and different batches of the
same stock between sites 2 and 3 in this experiment, which accounts for
the observed inter-site variation in TTP. As such we selected the ‘no
lysis’ condition for the in-tube protocol to avoid introducing un-
necessary processing steps and enhance technical simplicity.
When a preliminary in-tube protocol incorporating the ‘no lysis’
condition was applied to clinical samples from the three laboratory
sites, there was a significant effect of BCG vaccination detected at one
site, and trends at the other two. However, ability to observe statisti-
cally significant responses was likely limited by small sample size at site
1 (n=3) and early post-vaccination time-points at site 3 (weeks 2 and
4). It has previously been shown that the peak of response following
primary BCG vaccination in this assay occurs at 4–12 weeks post-vac-
cination, but may vary from individual to individual making it difficult
to reach statistical significance at a given time-point (Fletcher et al.,
2013; Joosten et al., 2018). The delay may be due to the time taken to
mount a vaccine-specific adaptive immune response, although it re-
mains to be determined whether this is the underlying mechanism re-
sponsible for the observed growth inhibition (Jensen et al., 2017;
Joosten et al., 2018). The lack of sensitivity to detect a vaccine response
may also be because the protocol used was not at this stage fully
Table 4
Inter-site reproducibility is improved by co-culturing in static 48-well plates
compared with rotating screw-cap tubes. Human PBMC from 12 donors were
co-cultured with BCG Pasteur in either sealed rotating screw-cap tubes or in
static 48-well plates with CO2. At the end of the 96 h culture period, the amount
of BCG remaining was quantified using the BACTEC MGIT system. The ex-
periment was repeated twice on different days across three different sites.
Intraclass correlation coefficient (ICC) and median coefficient of variation (CV)
values between sites averaged across runs are shown.
ICC CV (%)
Screw-cap tubes 0.20 20.39
48-well plates 0.33 12.84
Fig. 5. Assay harmonisation using relevant clinical
samples I. The MGIA using either 2ml screw-cap
tubes with 1× 106 PBMC per culture (a) or 48-well
plates with 3×106 PBMC per culture (b) was ap-
plied to a shared set of human PBMC from 20 donors;
10 of which were BCG-naïve (N, filled circles) and 10
of which were historically BCG vaccinated (B, open
circles). Each sample was assayed in duplicate to
assess intra-assay repeatability (c) and the experi-
ment conducted once at each of three different la-
boratories to measure inter-site reproducibility (d).
Growth ratio= log10(CFU of sample/CFU of con-
trol). Each point represents the mean of 2 or 3
technical co-culture replicates of the same sample
and lines represent the group median values with
interquartile range. A Wilcoxon matched-pairs
signed rank test was performed between groups,
where * indicates a p-value of< .05.
CV= coefficient of variation.
Fig. 6. Assay harmonisation using relevant clinical samples II. Cryopreserved
cells were taken from 9 UK adult volunteers at baseline and 12weeks post-BCG
vaccination and the direct PBMC MGIA performed across three different sites
using the optimised 48-well plate protocol only. Growth ratio= log10(CFU of
sample/CFU of control). Each point represents a sample cultured in singlicate
and lines represent the mean values with SEM. Data was found to be normally
distributed using a Shapiro-Wilk test so a paired t-test was performed, where *
indicates a p-value of< .05 and *** indicates a p-value of< .001.
R. Tanner, et al. Journal of Immunological Methods 469 (2019) 1–10
7
optimised for cell viability and functionality, as improved control of
mycobacterial growth following BCG vaccination has been described in
several other human MGIA studies (Cheng et al., 1988; Hoft et al.,
2002; Fletcher et al., 2013; Smith et al., 2016).
Due to this observed low sensitivity to detect a BCG vaccine re-
sponse and concerns regarding cell viability in the murine direct MGIA
using screw-cap tubes (Jensen et al., 2017), we compared the standard
in-tube protocol to a static 48-well plate adaptation described in mouse
splenocytes by Yang et al. (2016) (Yang et al., 2016). Co-culturing in
48-well tissue culture plates significantly improved total cell viability
by a mean of 23% at the end of the 96 h period. This is likely due to
availability of CO2 and lack of mechanical perturbation, which al-
though necessary to prevent the separation of whole blood cultures, is
damaging to the more fragile previously cryopreserved PBMC. Indeed, a
similar phenomenon was observed by Jensen et al. (2017) using the
direct mouse splenocyte MGIA whereby enrichment of the culture
medium by addition of nutrients and incubation in screw-cap tubes
without rotation increased cell viability from a mean of 21% to 46%
(Jensen et al., 2017).
Interestingly, viability was considerably better for human PBMC
(mean of 50% using the screw-cap tube protocol and 73% using the 48-
well plate protocol) compared with the values for murine splenocytes.
Murine splenocytes are widely considered more delicate than PBMC,
necessitating the use of fresh samples and suggesting that the human
MGIA may be more robust. However, other differences between these
studies may also have contributed including the use of virulent M.tb
Erdman in the murine study compared with BCG Pasteur, and different
MOIs (5× 106 cells with 50 CFUM.tb compared with 3×106 cells with
500 CFU BCG). Total cell viability did not correlate with control of
mycobacterial growth suggesting that cells dying over the 96 h in-
cubation period may not be those with effector functions. The con-
sistency in outcomes observed in a direct comparison of both assay
methods (Supplementary Fig. 1) supports this suggestion, although
such relationships are likely to be complex in a functional sum-of-the-
parts assay and it is unclear at what point during the culture period any
given cell type will mediate its effect.
IFN-γ production in response to mycobacterial infection, a measure
of cell functionality, was almost absent in supernatants at the end of the
co-culture period using screw-cap tubes. However, there was a sig-
nificant increase in IFN-γ concentrations measured following the 48-
well plate protocol. This is likely related to improved cell viability, as
supported by the significant association observed between these two
measures. The concentration of IFN-γ did not correlate with myco-
bacterial growth control, which is consistent with previous reports
using this and other MGIAs (Hoft et al., 2002; Kampmann et al., 2004;
Fletcher et al., 2013; Joosten et al., 2018). A lack of association suggests
that the assay is measuring parameters different from IFN-γ production
alone, supporting its use as an additional tool for assessing vaccine
immunogenicity. Use of 48-well plates also improved the repeatability,
intermediate precision and reproducibility compared with screw-cap
tubes - a finding that was replicated in the assay harmonisation phase of
the project using cells from BCG naïve and historically vaccinated vo-
lunteers. This may be a direct result of improved cell viability and
functionality, but it should also be noted that a lower cell number was
used in the screw-cap tubes for these experiments (1× 106 PBMC
compared with 3×106 PBMC used in the 48-well plate protocol) to
align with the standard in-tube protocol described in previous studies
(Fletcher et al., 2013; Smith et al., 2016; Tanner et al., 2017; Joosten
et al., 2018).
Tuomela et al. (2005) suggest that for assay validation a CV
of< 50% is acceptable variation for the measurement of a bacterial
target in a cell-based assay (Tuomela et al., 2005). Overall the precision
and reproducibility of the direct PBMC MGIA was remarkably high for a
cell-based functional assay. We found that repeatability (intra-assay
precision) was< 15% and < 5% CV for the screw-cap tube and 48-
well protocols respectively. Intermediate precision (inter-assay
precision) was<25% CV, while inter-site reproducibility was<30%
CV. Variability between sites is expected to be greater than between
assay runs at the same site which in turn is expected to be greater than
between replicates within a single run, as each level involves an ever-
greater number of opportunities to introduce variability. In a recent
multi-site study of technology transfer, CVs for inter-site reproducibility
for established standardised immunological assays such as ELISpot and
intracellular cytokine staining (ICS) were approximately 50% even after
side-by-side training (Smith et al., 2017), suggesting the direct MGIA
for both protocols to be a more consistent assay for immunological
monitoring of vaccination studies than the widely-used cytokine assays.
It should be noted, however, that cells were isolated and cryopreserved
at a single central facility, and thus potential effects of differential
PBMC processing and storage are not taken into account.
One criticism of using CV for such analysis is that the signal-to-noise
ratio is not taken into account. CV values may appear artificially low
because the range of values is small (including across the sample set), or
artificially high due to systematic differences. ICC compares within-
sample variability (between replicates within an assay run or between
runs) with between-sample variability and therefore arguably offers a
more stringent and meaningful measure. ICC can also be applied using a
‘consistency’ rather than ‘absolute’ agreement, which takes into account
systematic differences between operators. Thus ICC was also calculated
where sample size permitted. Using the criteria described by Landis and
Koch (1977), the ICC for repeatability (intra-assay precision) was
‘moderate’ for the in-tube protocol and ‘substantial’ for the 48-well
plate protocol. The ICC for intermediate (inter-assay) precision was
‘fair’ and ‘moderate’; while the ICC for inter-site reproducibility was
‘slight’ and ‘fair’ for the in-tube and 48-well plate protocols respec-
tively. Inter-site reproducibility may be improved by side-by-side
training of operators in the newly-defined SOP (Smith et al., 2017).
Standardising the BCG stock between sites also had a considerable
impact on inter-site reproducibility; in the first experiment where dif-
ferent BCG Pasteur stocks were used between sites 1 and 2/3 there was
a 2× difference between TTPs that was improved in subsequent ex-
periments where a common stock was shared.
In the final assay harmonisation phase of the project, we applied our
optimised assay conditions and standardised SOP (3× 106 cells,
500 CFU BCG, 48-well plates with CO2) to two shared sets of clinical
trial samples. In the first cohort, which consisted of BCG naïve and
historically vaccinated volunteers, we did not observe a difference be-
tween the two groups at any of the three sites or using either protocol.
That this finding was consistent across all three sites and both protocols
suggests that this is due to biological rather than technical factors.
These volunteers were vaccinated at various times in the past (up to
40 years ago) and as such we may not expect to detect an effect of
vaccination, particularly given that BCG efficacy has been shown to
reduce over time in some studies (Mangtani et al., 2018), and a pre-
vious study found the MGIA response to have waned by 24weeks post-
vaccination (Fletcher et al., 2013). However, given that a significant
effect was observed between naïve and historically-vaccinated in-
dividuals in an earlier experiment (Fig. 2b), this result may be due to
the particular donors used, as BCG is known to confer variable efficacy
in vivo.
A second clinical trial cohort was also tested where samples were
available from baseline and 12weeks post-vaccination. A significant
improvement in mycobacterial control was observed across all three
sites following vaccination using these samples, consistent with reports
of a BCG vaccine effect in several previous human MGIA studies (Cheng
et al., 1988; Kampmann et al., 2004; Fletcher et al., 2013; Smith et al.,
2016; Joosten et al., 2018) and high efficacy of BCG vaccination in this
(UK) population (Fine, 1995). In addition to using samples from re-
cently BCG-vaccinated volunteers, a further important difference be-
tween this and the previous harmonisation experiment was the addition
of autologous time-point matched serum rather than pooled human
serum to the MGIA co-cultures. Although data are not available from
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the same samples using pooled human serum, it has previously been
demonstrated that post-BCG-vaccination sera enhance mycobacterial
growth inhibition via antibody-mediated mechanisms (de Vallière et al.,
2005; Chen et al., 2016), and we suggest that use of autologous serum
offers a more representative ex vivo approach. This may be of particular
importance when assessing antibody-inducing vaccine candidates, and
merits further investigation in the context of this assay. We therefore
recommend the use of autologous serum where available. If pooled
human serum is used then preparation should be standardised; pre-
ferably using the same batch of commercially purchased human AB
serum which has been heat inactivated at 56 °C for 30min prior to
storing at −20 °C, and thawed at room temperature before addition to
co-cultures.
In conclusion, we have taken steps to optimise the human direct
PBMC MGIA and assess assay precision at multiple levels. We have
defined recommended assay conditions and noted that co-culturing in
48-well plates resulted in improved cell viability, IFN-γ production and
reproducibility between replicates, assay runs and sites. Based on these
findings, we produced a standardised operating procedure (SOP) using
3× 106 cells in 48-well plates with C02 which was applied to relevant
clinical samples. These conditions resulted in improved reproducibility
compared with a previously-described in-tube protocol using 1×106
cells, increasing the signal-to-noise ratio and ability to detect a vaccine-
induced response. However, we demonstrated that where dynamic
range is sufficient, there is moderate agreement between outcomes from
the two protocols, and that reproducibility of the in-tube protocol is still
well within acceptable limits for a cell-based functional assay (Tuomela
et al., 2005). As such, the in-tube protocol may be applied where cell
number is limiting and biological effects strong, and can be used to
further dissect the mechanism of mycobacterial growth control (Smith
et al., 2016; Tanner et al., 2017; Joosten et al., 2018). The optimisation
and harmonisation efforts described here resulted in demonstrable
consistency in outcomes between three laboratory sites using clinically-
relevant samples. This is a critical step in assay development to ensure
that comparable information can be extracted from TB vaccine studies
conducted across different organisations. Additional work is now re-
quired to further optimise and biologically validate the direct MGIA by
demonstrating a correlation with in vivo protection from mycobacterial
challenge, and to evaluate the performance of the assay in trials of
novel TB vaccine candidates.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jim.2019.01.006.
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